RecruitingPhase 3NCT07146022

Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA)

Studying Alopecia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Veradermics, Inc.
Principal Investigator
Reid Waldman, M.D., MD
Veradermics, Inc.
Intervention
VDPHL01 QD(drug)
Enrollment
552 target
Eligibility
18-65 years · FEMALE
Timeline
20252028

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07146022 on ClinicalTrials.gov

Other trials for Alopecia

Additional recruiting or active studies for the same condition.

See all trials for Alopecia

← Back to all trials